Insider Selling: Edwards Lifesciences Corp. CEO Unloads 29,500 Shares of Stock (EW)
Edwards Lifesciences Corp. (NYSE:EW) CEO Michael A. Mussallem sold 29,500 shares of the company’s stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $66.92, for a total transaction of $1,974,140.00. Following the sale, the chief executive officer now directly owns 263,850 shares in the company, valued at approximately $17,656,842. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Edwards Lifesciences Corp. (NYSE:EW) traded up 0.51% on Friday, hitting $66.94. The stock had a trading volume of 1,188,031 shares. Edwards Lifesciences Corp. has a 52 week low of $60.62 and a 52 week high of $90.31. The stock’s 50-day moving average is $67.04 and its 200-day moving average is $68.90. The company has a market cap of $7.324 billion and a price-to-earnings ratio of 18.94.
Edwards Lifesciences Corp. (NYSE:EW) last announced its earnings results on Monday, February 3rd. The company reported $0.91 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.82 by $0.09. The company had revenue of $536.00 million for the quarter, compared to the consensus estimate of $533.82 million. During the same quarter in the prior year, the company posted $0.77 earnings per share. The company’s quarterly revenue was up 5.0% on a year-over-year basis. On average, analysts predict that Edwards Lifesciences Corp. will post $3.05 earnings per share for the current fiscal year.
A number of research firms have recently commented on EW. Analysts at Leerink Swann raised their price target on shares of Edwards Lifesciences Corp. from $72.00 to $80.00 in a research note to investors on Tuesday, January 28th. Separately, analysts at Zacks downgraded shares of Edwards Lifesciences Corp. from a “neutral” rating to an “underperform” rating in a research note to investors on Monday, January 27th. They now have a $63.00 price target on the stock. Finally, analysts at Canaccord Genuity raised their price target on shares of Edwards Lifesciences Corp. from $74.00 to $78.00 in a research note to investors on Tuesday, January 14th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $73.24.
Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.